ARS Pharmaceuticals — Third Quarter 2026 Earnings Summary

ARS Pharmaceuticals reported third-quarter 2026 total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for its needle-free epinephrine product, neffy. The company achieved a 5% overall U.S. market share for neffy, with a 9% share in field-targeted accounts, while reducing third-quarter selling, general, and administrative expenses by 42% compared to the first-half 2026 average. ARS Pharma strengthened its leadership team with the appointments of Randall Kaye as Chief Medical Officer and John Slebir as Chief Legal Officer, and announced that interim Phase 2b data for its investigational drug ARS-2 in chronic spontaneous urticaria is expected in the first quarter of 2027. The company reported a net loss of $35.6 million for the quarter and maintains a cash position of $138.4 million as it pursues a path to cash flow breakeven by the end of 2027.